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Preanalytical conditions, be they due to the individual’s physi-
ologic state or to exogenous factors, can aﬀect coagulation
factors, in either a transient or a persistent manner, and need to
be considered in laboratory testing. These conditions include
physical and mental stress, diurnal variation, hormone levels
and posture at the time of blood drawing. While testing of these
factorshasnotbeenexhaustiveandsomeresultsareconﬂicting,
guidelines for testing conditions can be given.
Physical stress (exercise)
Exercise alters measures of coagulation and ﬁbrinolysis to a
variable extent depending on the intensity of the exercise. The
effect depends in part on the age and physical condition of the
subject [1,2]. Platelet aggregation in response to adenosine
diphosphate and epinephrine is enhanced during, and within
1 h after, moderate exercise. Plasma levels of serotonin and
b-thromboglobulin are increased after moderate exercise,
suggesting platelet activation [3]. Concentrations of factor (F)
VIII, von Willebrand factor antigen (VWF:Ag) and VWF
ristocetin cofactor activity (VWF:RCo) are increased up to 2.5-
fold, starting within 2–10 min and lasting for longer than 10 h
after ﬁnishing exercise, with greater effects with more intense
exercise [1,4]. No changes were observed in concentrations of
FXII, FV, FVII, FII or ﬁbrinogen after corrections for
hemoconcentration [4].
Activation of coagulation is reﬂected by an increase in
markers such as thrombin–antithrombin complexes (TAT),
prothrombin fragment 1 + 2 (F1+2 ) and ﬁbrinopeptide A
(FPA). Increased thrombin generation starts within 30 min
of moderate exercise. However, these increases do not
exceed reference intervals even during intense exercise [1,5].
An increase in global ﬁbrinolysis is observed during exercise
and immediately afterwards but soon returns to normal [4,6].
An increase in tissue plasminogen activator (t-PA) occurs early
and disappears within 2 h, while plasmin-a2-antiplasmin
complexes (PAP) are formed within 30 min and last for more
than 2 h. Concentrations of D-dimer rise quickly and the
increase persists for more than 1 h [1,5].
Mental stress
Mental stress can affect coagulation, although studies have
found conﬂicting results. With acute mental stress, FVIII,
VWF:Ag and VWF:RCo, ﬁbrinogen, and t-PA increase
[7,8,9]. Changes in menstruating women were greatest in the
luteal phase [9]. FVII was found to increase in men, but not
in women [8]. Another study found a decrease in VWF and
ﬁbrinogen, but this may have been due to a change in
plasma volume [10]. Prolonged mental stress (continuously
for 77 h) led to decreases in FV, FVIII and FIX. Only FIX
had recovered 5 days after the end of the stress. No increase
was observed in ﬁbrinolysis [11].
Hormonal inﬂuence
Pregnancy
Concentrations of most hemostatic proteins change to effect
an overall prothrombotic state during pregnancy [12],
presumably to protect women from bleeding at parturition.
Modest increases are found for FVII and FX. Fibrinogen
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and remain elevated for some period post partum; limited
data suggest individual variability in the length of time before
the levels return to baseline. The free protein S level decreases
by about 30% and may remain decreased for at least up to
2 months post partum [13–15]. Protein C remains within the
reference normal limits [12,13]. Classic and modiﬁed (using
FV-deﬁcient plasma) activated protein C (APC) ratios
decrease; the most pronounced changes are found with the
classic method [13,15]. The increased coagulation is reﬂected
by increased F1+2, TAT and soluble ﬁbrin [12,13]. With
regard to the ﬁbrinolytic system, both plasminogen activator
inhibitor-1 (PAI-1) and the placenta-produced PAI-2, as well
as D-dimer increase [12,13].
Contraceptives, hormonal replacement therapy (HRT) and
changes during menstrual cycle
The need to consider the phase of the menstrual cycle depends
upon what is being investigated. Estradiol concentrations are
lowest on cycle days (cd) 1–3 and highest on cd 13–15, followed
by a decrease. Progesterone concentrations are lowest on cd
1–8 and highest on cd 21–25.
Most hemostatic variables, such as FII, FX, FVII, anti-
thrombin, APC resistance, F1+2, plasminogen, a2-antiplas-
min, PAP, and D-dimer, show small or negligible changes with
the menstrual cycle [16–18]. Fibrinogen concentrations are
lowest during menstruation andhighest duringtheluteal phase.
The concentrations of FVII and FVIIa increase up to cd 14,
while protein S decreases between cd 1 and 14 [19,20]. The
bleeding time is longest during menstruation in most reports
[21].
A number of reports on changes in FVIII, VWF:Ag and
VWF:RCo [16,22–24] suggest that the concentrations are
highest during the luteal phase and lowest during the follicular
phase, while one study found no change [25]. However,
preanalytical conditions and cycle days for sampling differed
between these studies. VWF levels appear to be lowest on cd
1–4 [23].
In terms of hormonal therapy, inﬂuences on coagulation
depend in particular on estrogen content [26]. The inﬂuence of
progestins alone is not well-known. The degree of classic APC
resistance and other hemostatic changes induced by combined
hormonal contraceptives is modiﬁed by the progestin, with
levonorgestrel being the most effective in countering the
estrogen effect [27]. Currently prescribed hormonal contracep-
tives dampen the cyclic variation of VWF and ﬁbrinogen seen
in women not on hormonal contraceptives [22]. Regarding
combined contraceptives, no data support differences in
hemostasis by the mode of administration, be it oral,
transdermal or the vaginal ring, although there may be variable
absorption of hormones with a transdermal preparation.
Baseline epidemiological studies in healthy women under-
going menopause have demonstrated increased levels of several
coagulation factors, including FVIII and ﬁbrinogen. These
changes are due to both estrogen status and aging [28]. Several
studies have shown that initiation of estrogen therapy activates
the coagulation system in healthy postmenopausal women,
with increases in F1+2, FPA, decreased APC resistance
(classic method) and decreased free protein S noted [29–32].
The effect of transdermal HRT on coagulation is signiﬁcantly
less than that seen with oral preparations [31,32].
Circadian variation
Platelet aggregation is most pronounced and beta-thrombo-
globin concentrations are highest in the morning [33–36]. FV
activity, VWF:Ag and FVII antigen are unchanged, while
FVIII activity, FVIIa and F1+2 are highest in the morning, as
are protein C and S concentrations. Antithrombin is either
unchanged or peaks in the afternoon [34–36].
Global ﬁbrinolysis is lowest [6,37,38] in the early morning, as
is t-PA activity, while PAI-1 activity and antigen are highest at
that time. PAP is low in the morning and plasminogen is
unchanged [35,38]. Circadian variations in ﬁbrinolytic compo-
nents are not affected by lifestyle, dietary habits or ethnic
differences.
Posture
Posture during blood drawing is of importance, as the
hematocrit increases by up to 15% between lying down and
assuming a sitting position [39].
Dietary inﬂuences and smoking
The inﬂuences of fasting (totally overnight or only fat-fasting in
the morning), caffeine-containing beverages and smoking have
not been sufﬁciently investigated. However, lipemic plasma
interferes with many assays. Abstaining from smoking for 2 h
prior to the venipuncture is recommended, because of a
potential effect on platelet aggregation.
Recommendations to control preanalytical conditions in
obtaining coagulation studies
For venipuncture for coagulation studies, the patient should:
1 Abstain from intense physical exercise for at least 24 h and
from physical activity (rushing) just prior to venipuncture.
2 Be provided with an environment where physical stress and
mental stress are lessened.
3 Abstain from fatty foods and smoking on the morning of the
venipuncture; the patient should be fasting for PAI-1 and
global ﬁbrinolysis assays.
4 Have samples obtained early in the morning (7.00–9.00 AM)
after sitting in a relaxed position for 20–30 min.
Speciﬁcally for women:
1 For the diagnosis of von Willebrand disease (VWD) in fertile
women, blood samples should be obtained on cd 1–4. This
may aid in the diagnosis in women with borderline values
obtained at other times.
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drawn for at least 2 months before testing. This is especially
true for testing of free protein S, protein S activity and APC
resistance (classic method).
3 For the diagnosis of inherited disorders of hemostasis
(particularly VWD, FVIII deﬁciency, and protein S deﬁci-
ency) samples should be obtained when normal menstrual
cycles have returned or at least 2 months post partum. All
abnormal values obtained in connection with pregnancy,
including testing for phospholipid antibodies, should be
veriﬁed with repeat blood sampling.
Areas of study needed
Standardized international studies of potential inﬂuences on
coagulation, especially hormonal inﬂuences, should be per-
formed using newer global hemostatic assays. Because of the
signiﬁcance of VWD and disorders of platelet function
resulting in bleeding symptoms in women, improved under-
standing of hormonal effects on these factors, and improved
laboratory testing for such, is needed.
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